EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions

Zachary Philippi, Keerthi D Reddy, Sheza Malik, Zeina Al-Khalil iD, Nader Dbouk iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26135994 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Zachary Philippi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), the most common primary liver cancer, remains a leading cause of cancer-related mortality worldwide. Its often-silent progression results in late-stage diagnosis, limiting curative options and necessitating systemic therapy for many patients. The presence of underlying cirrhosis in most cases further complicates treatment decisions. While the approval of sorafenib in 2007 marked a major milestone in systemic therapy for HCC, the treatment landscape has since evolved significantly, particularly with the advent of immune checkpoint inhibitors and anti-angiogenic agents. Combination regimens, such as atezolizumab plus bevacizumab, have demonstrated superior outcomes and are now considered standard first-line options. Despite these advances, efforts to translate insights from HCC’s molecular pathogenesis into personalized treatments have been limited. This narrative review explores the current systemic therapy options for HCC, from first-line to subsequent-line treatments, and highlights emerging strategies, including novel immunotherapies and targeted agents. We emphasize the need for individualized treatment approaches that consider tumor biology, liver function, and performance status, and we outline future directions for research aimed at improving outcomes in this complex and evolving field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansImmunotherapyImmune Checkpoint InhibitorsAngiogenesis InhibitorsMolecular Targeted Therapy

Stichwörter der Autor:innen

emerging therapieshepatocellular carcinomaimmune checkpoint inhibitorssystemic therapytyrosine kinase inhibitors

Substanzen

Immune Checkpoint InhibitorsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Rochester General Hospital, Rochester, NY 14621, USA.
  • School of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon.
  • Emory Transplant Center, Atlanta, GA 30322, USA.

ORCID-Profile: Zeina Al-Khalil, Nader Dbouk

Zitieren

APA

Philippi, Z., Reddy, K. D., Malik, S., Al-Khalil, Z., & Dbouk, N. (2025). Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26135994

Vancouver

Philippi Z, Reddy KD, Malik S, Al-Khalil Z, Dbouk N. Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26135994

BibTeX
@article{Philippi2025,
  author = {Philippi, Zachary and Reddy, Keerthi D and Malik, Sheza and Al-Khalil, Zeina and Dbouk, Nader},
  title = {Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26135994}
}
Kostenlos starten →